Sempra (SRE) Stock Forecast
Data as of May 2, 2026Utilities · Current price $94.86 (-0.25%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 3, 2026 | Nicholas Campanella | Barclays | $95.00 | +0.1% |
| Feb 2, 2026 | David Arcaro | Morgan Stanley | $97.00 | +2.3% |
| Jan 22, 2026 | Nicholas Campanella | Barclays | $97.00 | +2.3% |
| Jan 20, 2026 | Shahriar Pourreza | Wells Fargo | $112.00 | +18.1% |
| Oct 22, 2025 | David Arcaro | Morgan Stanley | $99.00 | +4.4% |
| Oct 22, 2025 | James Thalacker | BMO Capital | $99.00 | +4.4% |
| Jul 10, 2025 | Nicholas Campanella | Barclays | $71.00 | -25.2% |
| May 22, 2025 | David Arcaro | Morgan Stanley | $87.00 | -8.3% |
| Apr 23, 2025 | David Arcaro | Morgan Stanley | $89.00 | -6.2% |
| Apr 14, 2025 | Julien Dumoulin-Smith | Jefferies | $75.00 | -20.9% |
| Oct 24, 2024 | Julian Dumoulin-Smith | Jefferies | $98.00 | +3.3% |
| Oct 21, 2024 | James Thalacker | BMO Capital | $96.00 | +1.2% |
| Oct 21, 2024 | Anthony Crowdell | Mizuho Securities | $93.00 | -2.0% |
| Oct 1, 2024 | Nicholas Campanella | Barclays | $89.00 | -6.2% |
| Sep 25, 2024 | David Arcaro | Morgan Stanley | $85.00 | -10.4% |
| Sep 12, 2024 | James Thalacker | BMO Capital | $93.00 | -2.0% |
| Aug 23, 2024 | David Arcaro | Morgan Stanley | $80.00 | -15.7% |
| Aug 16, 2024 | Anthony Crowdell | Mizuho Securities | $88.00 | -7.2% |
| Aug 13, 2024 | Nicholas Campanella | Barclays | $87.00 | -8.3% |
| Aug 9, 2024 | James Thalacker | BMO Capital | $90.00 | -5.1% |
Top Analysts Covering SRE
SRE vs Sector & Market
| Metric | SRE | Utilities Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.28 | 2.62 | 2.41 |
| Analyst Count | 18 | 9 | 18 |
| Target Upside | +12.8% | +49.8% | +14.9% |
| P/E Ratio | 34.40 | -3.54 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $13.61B | $14.33B | $14.85B | 9 |
| 2027-12-31 | $12.41B | $13.63B | $14.84B | 9 |
| 2028-12-31 | $13.87B | $14.05B | $14.23B | 10 |
| 2029-03-31 | $3.29B | $4.03B | $4.35B | 3 |
| 2029-06-30 | $3.31B | $4.05B | $4.37B | 2 |
| 2029-09-30 | $3.32B | $4.08B | $4.39B | 2 |
| 2029-12-31 | $3.34B | $4.10B | $4.42B | 3 |
| 2030-03-31 | $3.36B | $4.12B | $4.44B | 3 |
| 2030-06-30 | $3.38B | $4.14B | $4.46B | 2 |
| 2030-09-30 | $3.40B | $4.16B | $4.49B | 2 |
| 2030-12-31 | $3.41B | $4.18B | $4.51B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4.69 | $5.11 | $5.46 | 8 |
| 2027-12-31 | $5.19 | $5.51 | $5.70 | 8 |
| 2028-12-31 | $5.86 | $5.99 | $6.11 | 2 |
| 2029-03-31 | $1.40 | $1.84 | $2.03 | 4 |
| 2029-06-30 | $1.03 | $1.35 | $1.49 | 2 |
| 2029-09-30 | $1.14 | $1.50 | $1.65 | 2 |
| 2029-12-31 | $1.39 | $1.83 | $2.01 | 2 |
| 2030-03-31 | $1.54 | $2.03 | $2.23 | 2 |
| 2030-06-30 | $1.15 | $1.51 | $1.66 | 2 |
| 2030-09-30 | $1.27 | $1.67 | $1.84 | 5 |
| 2030-12-31 | $1.50 | $1.98 | $2.18 | 5 |
Frequently Asked Questions
What is the analyst consensus for SRE?
The consensus among 18 analysts covering Sempra (SRE) is Buy with an average price target of $100.88.
What is the highest price target for SRE?
The highest price target for SRE is $156.00, set by Eric Beaumont at Barclays on 2023-10-19.
What is the lowest price target for SRE?
The lowest price target for SRE is $36.25, set by Sarah Akers at Wells Fargo on 2021-11-08.
How many analysts cover SRE?
18 analysts have issued ratings for Sempra in the past 12 months.
Is SRE a buy or sell right now?
Based on 18 analyst ratings, SRE has a consensus rating of Buy (2.28/5) with a +12.8% upside to the consensus target of $100.88.
What are the earnings estimates for SRE?
Analysts estimate SRE will report EPS of $5.11 for the period ending 2026-12-31, with revenue estimated at $14.33B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.